This is a working overview of dihexa, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
== History == 4-HO-NiPT was first described in the scientific literature, as a metabolite of 4-AcO-DiPT, in 2022. Subsequently, its synthesis was described in 2023 and its pharmacology was reported in 2024. The drug was reported as a possible novel designer drug online in 2022.
A ligament is a small band of dense, white, fibrous elastic tissue. Ligaments connect the ends of bones together in order to form a joint. Most ligaments limit dislocation, or prevent certain movements that may cause breaks. Since they are only elastic they increasingly lengthen when under pressure. When this occurs the ligament may be susceptible to break resulting in an unstable joint. Ligaments may also restrict some actions: movements such as hyper extension and hyper flexion are restricted by ligaments to an extent. Also ligaments prevent certain directional movement.
The integration of such columns allows for experiments to be run where materials were in low availability or very expensive, like in biological analysis of proteins. This reduction in reagent volumes allows for new experiments like single-cell protein analysis, which due to size limitations of prior devices, previously came with great difficulty. The coupling of HPLC-chip devices with other spectrometry methods like mass-spectrometry allow for enhanced confidence in identification of desired species, like proteins. Microfluidic chips have also been created with internal delay-lines that allow for gradient generation to further improve HPLC, which can reduce the need for further separations. Some other practical applications of integrated HPLC chips include the determination of drug presence in a person through their hair and the labeling of peptides through reverse phase liquid chromatography.
At the 2015 China Victory Day Parade, Xi announced a reduction of 300,000 troops from the PLA, bringing its size to 2 million troops. Xi described this as a gesture of peace, while analysts have said that the cut was done to reduce costs as well as to modernize the PLA. In November 2015, the Central Leading Group for Military Reform announced extensive reforms in the PLA called Deepening National Defense and Military Reform. In 2016, Xi reduced the number of theater commands of the PLA from seven to five. He also abolished the four autonomous general departments of the PLA, replacing them with 15 agencies directly reporting to the CMC. Two new branches of the PLA were created under his reforms, the Strategic Support Force and the Joint Logistics Support Force. PLA Second Artillery Corps was upgraded to the PLA Rocket Force. In March 2016, the CMC announced the abolishment of paid services by the PLA and the People's Armed Police (PAP) by 2019, meaning activities like military-run hospitals and hotels open to the public. On 21 April 2016, Xi was named commander-in-chief of the country's new CMC Joint Operations Command Center. In 2018, the PAP was placed under the sole control of the CMC; it was previously under the joint command of the CMC and the State Council through the Ministry of Public Security. The PLA went through further extensive reforms in 2024; the Strategic Support Force was dissolved and the Aerospace Force, the Cyberspace Force and the Information Support Force was established as arms of the PLA, joining the Joint Logistics Support Force.
Sources: en.wikipedia.org
In living cells, DNP acts as a protonophore, an agent that can shuttle protons (hydrogen cations) across biological membranes. It dissipates the proton gradient across the mitochondrial membrane, collapsing the proton motive force that the cell uses to produce most of its ATP chemical energy. Instead of producing ATP, the energy of the proton gradient is lost as heat. The inefficiency is proportional to the dose of DNP that is taken. As the dose increases and energy production is made more inefficient, metabolic rate increases (and more fat is burned) in order to compensate for the inefficiency and to meet energy demands. DNP is probably the best known agent for uncoupling oxidative phosphorylation. The phosphorylation of adenosine diphosphate (ADP) by ATP synthase gets disconnected or uncoupled from oxidation. DNP raises the basal metabolic rate (BMR) and lowers T4 (thyroid hormone) levels by increasing T4 metabolism and reducing thyroid hormone secretion. Because it binds to thyroxine-binding globulin, overall thyroid function may not be affected. DNP cannot substitute for thyroid hormone in myxedema.
== Awards == In 2008, Horsley was a regional finalist in the Blavatnik Awards for Young Scientists. In 2012, Horsley received the Presidential Early Career Award for Scientists and Engineers for her research of skin cell generation. Also in 2012, she was one of two recipients and received the Rosalind Franklin Young Investigator Award, presented every three years by the Genetics Society of America and the American Society of Human Genetics to two top women scientists in the field of genetics. In 2016, Horsley received the Montagna Lecture Award from the Society of Investigative Dermatology. In 2018, Horsley received the Graduate Division in Biomedical and Biological Sciences Distinguished Alumnus award from Emory University. Horsley's work and lab are supported by federal funding from the National Institutes of Health.
Within two years, they had opened 29 stores in Singapore and Malaysia, almost as many stores as the Hymans had opened in their 35 years of ownership. In 1998, the Sassoons, along with longtime friend Severin Wunderman, purchased the parent company, International Coffee & Tea LLC, from the Hymans, and took it global. Victor Sassoon worked out of Singapore, Sunny Sassoon worked in Los Angeles, and Wunderman was a silent partner with no role in management. International Coffee & Tea, LLC remained the name of the holding company. Sunny Sassoon served as president and CEO from 1998 until 2009, when he moved to the executive chairman position until 2019. In 2009, Mel Elias (Sassoon's brother-in-law) assumed the role of president and CEO of the company, after spending seven years as chief operating officer. In September 2013, a significant equity position in Coffee Bean was acquired from International Coffee & Tea by US-based Advent International, in partnership with South Korea-based Mirae Asset Private Equity and Taiwan-based CDIB Capital. The Sassoon family remains a large shareholder. John Fuller served as president and CEO from 2015 to 2020. In April 28, 2014, Hyman died at the age of 82. He had heart disease. In 2019, the Philippines' Jollibee Foods Corporation (JFC) acquired The Coffee Bean & Tea Leaf for $350 million, making it Jollibee's biggest investment at the time. JFC bought it through Java Ventures LLC, a company from the US that is a wholly owned subsidiary of Super Magnificent Coffee Company Pte. Ltd. in Singapore, a subsidiary of Jollibee Worldwide Pte Ltd.
Sources: en.wikipedia.org
== Limitations == Because the Edman degradation proceeds from the N-terminus of the protein, it will not work if the N-terminus has been chemically modified (e.g. by acetylation or formation of pyroglutamic acid). Sequencing will stop if a non-α-amino acid is encountered (e.g. isoaspartic acid), since the favored five-membered ring intermediate is unable to be formed. Edman degradation is generally not useful to determine the positions of disulfide bridges. Protein sequencing of attomole level of Edman degraded sequences are obtainable but require accelerator mass spectrometery which requires large, complex, and expensive equipment as well as 30 hours of bench time to analyze a single run.
=== Salt metathesis === Silver nitrate is a precursor for the laboratory-scale synthesis of many silver compounds. These include the dark brown oxide, yellow iodide, pale yellow bromide, and white chloride. Among the oxyanion derivatives, the following compounds can be produced by precipitation from aqueous silver nitrate: the white sulfate, white sulfite, pale yellow nitrite, and pale yellow carbonate. When making photographic film, silver nitrate is treated with halide salts of sodium or potassium to form insoluble silver halide in situ in photographic gelatin, which is then applied to strips of tri-acetate or polyester. Similarly, silver nitrate is used to prepare some silver-based explosives, such as the fulminate, azide, or acetylide, through a precipitation reaction.
=== Brain Natriuretic Peptide (BNP) === BNP was first discovered in pig brain tissue but was later found more abundant in the heart (Mukoyama et al. 1991; Mukoyama et al. 1990). The human gene that encodes for BNP is called NPPB (GeneID 4879) and is located on chromosome 1 at 1p36.2. In mice, NPPb is found on chromosome 4. NPPB has three exons and two introns, and its preproBNP comprises 134 amino acids. This includes a 26 amino acid signal sequence followed by 108 amino acids that contain proBNP. Unlike ANP, the sequence of BNP is not similar across different species.
The presidency of Ronald Reagan (1981–89) saw a significant increase in federal focus on drug interdiction and prosecution. Shortly after his inauguration, Reagan announced, "We're taking down the surrender flag that has flown over so many drug efforts; we're running up a battle flag." From 1980 to 1984, the annual budget of the Federal Bureau of Investigation (FBI) drug enforcement units went from $8 million to $95 million. In 1982, Vice President George H. W. Bush and his aides began pushing for the involvement of the Central Intelligence Agency (CIA) and the US military in drug interdiction efforts. Early in the Reagan term, First Lady Nancy Reagan, with the help of an advertising agency, began her youth-oriented "Just Say No" anti-drug campaign. Propelled by the First Lady's tireless promotional efforts through the 1980s, "Just Say No" entered the American vernacular. Later research found that the campaign had little or no impact on youth drug use. One striking change attributed to the effort: public perception of drug abuse as America's most serious problem, in the 2–6% range in 1985, rose to 64% in 1989. In January 1982, Reagan established the South Florida Task Force, chaired by Bush, targeting a surge of cocaine and cannabis entering through the Miami region, and the sharp rise in related crime. The project involved the DEA, the Customs Service, the FBI and other agencies, and Armed Forces ships and planes. It was called the "most ambitious and expensive drug enforcement operation" in US history; critics called it an election year political stunt.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.